226 related articles for article (PubMed ID: 20005148)
21. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Guo Y; Wang S; Hoot DR; Clinton SK
J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
[TBL] [Abstract][Full Text] [Related]
22. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
Borgström P; Gold DP; Hillan KJ; Ferrara N
Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
[TBL] [Abstract][Full Text] [Related]
23. Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis.
Tsutsumi N; Yonemitsu Y; Shikada Y; Onimaru M; Tanii M; Okano S; Kaneko K; Hasegawa M; Hashizume M; Maehara Y; Sueishi K
Circ Res; 2004 May; 94(9):1186-94. PubMed ID: 15059936
[TBL] [Abstract][Full Text] [Related]
24. VEGF inhibition: insights from preclinical and clinical studies.
Crawford Y; Ferrara N
Cell Tissue Res; 2009 Jan; 335(1):261-9. PubMed ID: 18766380
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets.
Vizán P; Sánchez-Tena S; Alcarraz-Vizán G; Soler M; Messeguer R; Pujol MD; Lee WN; Cascante M
Carcinogenesis; 2009 Jun; 30(6):946-52. PubMed ID: 19369582
[TBL] [Abstract][Full Text] [Related]
26. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
27. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
[TBL] [Abstract][Full Text] [Related]
28. Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
Shojaei F
Cancer Lett; 2012 Jul; 320(2):130-7. PubMed ID: 22425960
[TBL] [Abstract][Full Text] [Related]
29. Targeting inflammatory cells to improve anti-VEGF therapies in oncology.
Gerber HP; Olazoglu E; Grewal IS
Recent Results Cancer Res; 2010; 180():185-200. PubMed ID: 20033384
[TBL] [Abstract][Full Text] [Related]
30. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.
Lieu C; Heymach J; Overman M; Tran H; Kopetz S
Clin Cancer Res; 2011 Oct; 17(19):6130-9. PubMed ID: 21953501
[TBL] [Abstract][Full Text] [Related]
31. [Mechanisms of resistance to inhibitors of the VEGF pathway].
Bousquet G; Varna M; Janin A
Ann Pathol; 2010 Nov; 30(5 Suppl 1):40-1. PubMed ID: 21055540
[No Abstract] [Full Text] [Related]
32. [Molecular bases of tumor angiogenesis].
Corvol P
Ann Pathol; 2010 Nov; 30(5 Suppl 1):32-6. PubMed ID: 21055538
[No Abstract] [Full Text] [Related]
33. An integrative model for vascular endothelial growth factor A as a tumour biomarker.
Latham AM; Molina-París C; Homer-Vanniasinkam S; Ponnambalam S
Integr Biol (Camb); 2010 Sep; 2(9):397-407. PubMed ID: 20725676
[TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis.
Eswarappa SM; Fox PL
Cancer Res; 2015 Jul; 75(14):2765-9. PubMed ID: 26122849
[TBL] [Abstract][Full Text] [Related]
35. Blood vessels as targets in tumor therapy.
Claesson-Welsh L
Ups J Med Sci; 2012 May; 117(2):178-86. PubMed ID: 22348394
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin.
Kandalaft LE; Motz GT; Busch J; Coukos G
Curr Top Microbiol Immunol; 2011; 344():129-48. PubMed ID: 20680802
[TBL] [Abstract][Full Text] [Related]
37. Anti-angiogenic active immunotherapy: a new approach to cancer treatment.
Pan J; Jin P; Yan J; Kabelitz D
Cancer Immunol Immunother; 2008 Aug; 57(8):1105-14. PubMed ID: 18214475
[TBL] [Abstract][Full Text] [Related]
38. Vascular hyperpermeability, angiogenesis, and stroma generation.
Nagy JA; Dvorak AM; Dvorak HF
Cold Spring Harb Perspect Med; 2012 Feb; 2(2):a006544. PubMed ID: 22355795
[TBL] [Abstract][Full Text] [Related]
39. Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel by Francesco Bertolini.
Kerbel R
Int J Dev Biol; 2011; 55(4-5):395-8. PubMed ID: 21858765
[TBL] [Abstract][Full Text] [Related]
40. [Characteristics of tumor endothelial cells].
Hida K
Seikagaku; 2012 Jan; 84(1):43-6. PubMed ID: 22416472
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
